A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Acronyms OSTRO
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 22 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 17 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top